Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$81.15 -0.6%	$42.55	$4.77 ▼ $81.95	$6.13B	0.56	662,587 shs	39,429 shs
AUPH Aurinia Pharmaceuticals	$12.05 -0.5%	$9.81	$6.42 ▼ $12.53	$1.60B	1.23	2.84 million shs	1.08 million shs
LEGN Legend Biotech	$34.65 +0.8%	$37.77	$27.34 ▼ $59.62	$6.35B	0.26	1.44 million shs	1,625 shs
RNA Avidity Biosciences	$48.90 +0.7%	$37.05	$21.51 ▼ $56.00	$6.28B	0.95	1.84 million shs	590 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+2.78%	+9.69%	+16.96%	+1,260.67%	+565.91%
AUPH Aurinia Pharmaceuticals	-0.25%	0.00%	+35.12%	+53.69%	+82.75%
LEGN Legend Biotech	-1.01%	-3.26%	-15.70%	+19.55%	-39.34%
RNA Avidity Biosciences	+1.59%	+8.78%	+35.13%	+56.81%	+11.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX Abivax	2.6989 of 5 stars	3.6	3.0	3.0	0.8	0.6
AUPH Aurinia Pharmaceuticals	2.9874 of 5 stars	1.5	3.0	3.6	2.5	3.1
LEGN Legend Biotech	3.8905 of 5 stars	4.5	4.0	3.4	1.7	0.6
RNA Avidity Biosciences	3.1495 of 5 stars	4.5	2.0	4.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.13	Buy	$92.33	13.78% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$12.00	-0.41% Downside
LEGN Legend Biotech	2.91	Moderate Buy	$74.22	114.23% Upside
RNA Avidity Biosciences	3.06	Buy	$67.00	37.01% Upside

Current Analyst Ratings Breakdown

Latest AUPH, LEGN, ABVX, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	LEGN Legend Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$66.00
8/25/2025	LEGN Legend Biotech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$77.00 ➝ $78.00
8/12/2025	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$75.00 ➝ $77.00
8/12/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$81.00 ➝ $83.00
8/8/2025	RNA Avidity Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00
8/8/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$59.00 ➝ $62.00
8/8/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
8/4/2025	LEGN Legend Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/1/2025	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
7/30/2025	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00
7/29/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $112.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
AUPH Aurinia Pharmaceuticals	$235.13M	6.75	$0.31 per share	39.26	$2.55 per share	4.73
LEGN Legend Biotech	$796.84M	7.99	N/A	N/A	$5.64 per share	6.14
RNA Avidity Biosciences	$10.90M	577.15	N/A	N/A	$9.27 per share	5.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	$5.75M	$0.43	28.19	21.52	N/A	23.31%	20.06%	13.81%	11/6/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.88	N/A	N/A	N/A	-40.83%	-32.00%	-20.07%	11/11/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.56	N/A	N/A	N/A	-4,247.77%	-33.45%	-30.22%	11/6/2025 (Estimated)

Latest AUPH, LEGN, ABVX, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	LEGN Legend Biotech	-$0.22	-$0.34	-$0.12	-$0.34	$237.49 million	$255.06 million
7/31/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.17	$0.16	-$0.01	$0.16	$64.27 million	$70.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	1.25	1.25
AUPH Aurinia Pharmaceuticals	0.18	5.23	4.63
LEGN Legend Biotech	0.30	4.71	4.57
RNA Avidity Biosciences	N/A	9.26	9.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
AUPH Aurinia Pharmaceuticals	36.83%
LEGN Legend Biotech	70.89%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
AUPH Aurinia Pharmaceuticals	12.20%
LEGN Legend Biotech	0.02%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	75.57 million	N/A	Not Optionable
AUPH Aurinia Pharmaceuticals	300	131.63 million	115.57 million	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
RNA Avidity Biosciences	190	128.65 million	123.73 million	Optionable

AUPH, LEGN, ABVX, and RNA Headlines

Recent News About These Companies

Invesco Ltd. Purchases 193,376 Shares of Avidity Biosciences, Inc. $RNA

August 28 at 3:26 AM | marketbeat.com

Avidity Biosciences to Participate in Upcoming Investor Conferences

August 27 at 9:00 AM | prnewswire.com

BI Asset Management Fondsmaeglerselskab A S Sells 52,463 Shares of Avidity Biosciences, Inc. $RNA

August 27 at 4:26 AM | marketbeat.com

Price T Rowe Associates Inc. MD Purchases 295,275 Shares of Avidity Biosciences, Inc. $RNA

August 26 at 4:58 AM | marketbeat.com

771,158 Shares in Avidity Biosciences, Inc. $RNA Acquired by T. Rowe Price Investment Management Inc.

August 26 at 4:49 AM | marketbeat.com

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

August 25, 2025 | zacks.com

Nuveen LLC Invests $12.73 Million in Avidity Biosciences, Inc. $RNA

August 24, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Insider Sells $102,451.20 in Stock

August 23, 2025 | insidertrades.com

Candriam S.C.A. Increases Stock Position in Avidity Biosciences, Inc. $RNA

August 23, 2025 | marketbeat.com

Wellington Management Group LLP Has $285.89 Million Stock Holdings in Avidity Biosciences, Inc. $RNA

August 22, 2025 | marketbeat.com

Aberdeen Group plc Increases Holdings in Avidity Biosciences, Inc. $RNA

August 22, 2025 | marketbeat.com

Avidity Biosciences, Inc. $RNA Shares Sold by Swiss National Bank

August 22, 2025 | marketbeat.com

Avidity Biosciences Sees Unusually High Options Volume (NASDAQ:RNA)

August 21, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Down 4.2% on Insider Selling

August 20, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $67.00 Consensus PT from Analysts

August 20, 2025 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Stock Price Down 4.2% on Insider Selling

August 20, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. $RNA Holdings Cut by Vanguard Group Inc.

August 19, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Citigroup Inc.

August 18, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Deutsche Bank AG

August 18, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $465,600.00 in Stock

August 17, 2025 | marketbeat.com

Teresa Mccarthy Sells 10,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

August 16, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH, LEGN, ABVX, and RNA Company Descriptions

Abivax NASDAQ:ABVX

$81.15 -0.49 (-0.60%)

As of 09:47 AM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Aurinia Pharmaceuticals NASDAQ:AUPH

$12.05 -0.06 (-0.50%)

As of 09:48 AM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Legend Biotech NASDAQ:LEGN

$34.65 +0.28 (+0.80%)

As of 09:47 AM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Avidity Biosciences NASDAQ:RNA

$48.90 +0.32 (+0.66%)

As of 09:48 AM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time